FDA grants De Novo authorization for noninvasive device to treat varicose veins
Theraclion has announced that the US Food and Drug Administration (FDA) has granted De Novo authorization for its Sonovein device to treat superficial venous reflux in great saphenous veins (GSV), the main cause of varicose veins.
Read original article on The Medical News →